NCT05283720 2026-03-03A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaGenmabPhase 2 Recruiting496 enrolled
NCT04421560 2026-02-20Pembrolizumab, Ibrutinib and Rituximab in PCNSLDana-Farber Cancer InstitutePhase 1/2 Recruiting37 enrolled
NCT06644183 2026-02-11Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)Dana-Farber Cancer InstitutePhase 1/2 Recruiting64 enrolled
NCT07001540 2025-06-19Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous TransplantationFudan UniversityPhase 2 Recruiting130 enrolled